<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CHLORPHENIRAMINE MALEATE</span><br/>(klor-fen-eer'a-meen)<br/><span class="topboxtradename">Aller-Chlor, </span><span class="topboxtradename">Chlo-Amine, </span><span class="topboxtradename">Chlorate, </span><span class="topboxtradename">Chlor-Pro, </span><span class="topboxtradename">Chlorspan, </span><span class="topboxtradename">Chlortab, </span><span class="topboxtradename">Chlor-Trimeton, </span><span class="topboxtradename">Chlor-Tripolon <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Novopheniram <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Pfeiffer Allergy, </span><span class="topboxtradename">Phenetron, </span><span class="topboxtradename">Telachlor, </span><span class="topboxtradename">Teldrin, </span><span class="topboxtradename">Trymegan<br/></span><b>Classifications:</b> <span class="classification">antihistamine (h<sub>1</sub>-receptor antagonist)</span><br/><b>Prototype: </b>Diphenhydramine<br/><b>Pregnancy Category: </b>B first and second trimester; category; D in third trimester<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg, 4 mg tablets; 8 mg, 12 mg sustained-release tablets; 2 mg/5 mL syrup</p>
<h1><a name="action">Actions</a></h1>
<p>Antihistamine that competes with histamine for H<sub>1</sub>-receptor sites on effector cells, thus it prevents histamine action that promotes capillary permeability and edema formation
         and constrictive action on respiratory, gastrointestinal, and vascular smooth muscles. It generally produces less drowsiness
         than other antihistamines, but adverse effects involving CNS stimulation may be more common.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Has effective antihistamine reaction resulting in decreasing allergic symptomatology.</p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic relief of various uncomplicated allergic conditions; to prevent transfusion and drug reactions in susceptible
         patients, and as adjunct to epinephrine and other standard measures in anaphylactic reactions.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to antihistamines of similar structure; lower respiratory tract symptoms, narrow-angle glaucoma, obstructive
         prostatic hypertrophy or other bladder neck obstruction, GI obstruction or stenosis; pregnancy (category B in first and second
         trimester and category D in third trimester), lactation; premature and newborn infants; during or within 14 d of <small>MAO INHIBITOR</small> therapy.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Convulsive disorders, increased intraocular pressure, hyperthyroidism, cardiovascular disease, hypertension, diabetes mellitus,
         history of bronchial asthma, older adult patients, patients with G6PD deficiency.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Symptomatic Allergy Relief</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 24 mg t.i.d. or q.i.d. <i>or</i> 812 mg b.i.d. or t.i.d., max: 24 mg/d<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 4 mg q.d. or b.i.d. <i>or</i> 8 mg sustained-release h.s.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>612 y:</i> 2 mg q46h (max: 12 mg/d); <i>26 y:</i> 1 mg q46h<br/><br/><span class="indicationtitle">Allergic Reactions to Blood</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC/IV/IM</span> 1020 mg (max: 40 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach for fastest response.</li>
<li>Sustained-release tablets should be swallowed whole and not crushed or chewed.</li>
<li>Ensure that chewable tablets are chewed or crushed before being swallowed with a liquid.</li>
</ul><span class="adminroutetype">Subcutaneous/</span><span class="adminroutetype">Intramuscular/</span><span class="adminroutetype">Intravenous</span><br/><ul>
<li>The 100 mg/mL preparation is intended for IM or SC use only. It should not be administered IV because it contains preservatives.
            The 10 mg/mL injection can be given IV, IM, or SC. It contains no preservatives.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 10 mg or fraction thereof over at least 1 min.  
               </p>
<ul>
<li>If patient manifests any reaction after parenteral administration, drug should be discontinued. (Exception: Patient may experience
                     transitory stinging sensation that rarely lasts longer than a few minutes.)
                  </li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store preferably between 15° and 30° C (59° and 86° F) unless otherwise directed by manufacturer. Syrup
            and injection forms should be protected from light to prevent discoloration.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Sensation of chest tightness. <span class="typehead">CV:</span> Palpitation, tachycardia, mild hypotension or hypertension. <span class="typehead">GI:</span> Epigastric distress, anorexia, nausea, vomiting, constipation, or diarrhea. <span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness,</span> sedation, headache, dizziness, vertigo, fatigue, disturbed coordination, tremors, euphoria, nervousness, restlessness, insomnia.
       <span class="typehead">Special Senses:</span>
<span class="speceff-common">Dryness of mouth,</span> nose, and throat, tinnitus, vertigo, acute labyrinthitis, thickened bronchial secretions, blurred vision, diplopia. <span class="typehead">Urogenital:</span> Urinary frequency or retention, dysuria. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Antihistamines should be discontinued 4 d before <span class="alt">skin testing</span> procedures for allergy because they may obscure otherwise positive reactions.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b> Alcohol (ethanol)</b> and other <span class="classification">cns depressants</span> produce additive sedation and CNS depression. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from GI tract; about 45% of dose reaches systemic circulation intact. <span class="typehead">Onset:</span> Within 6 h. <span class="typehead">Peak:</span> 26 h. <span class="typehead">Distribution:</span> Highest concentrations in lung, heart, kidney, brain, small intestine, and spleen. <span class="typehead">Half-Life:</span> 1243 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for CNS depression and sedation, especially when chlorpheniramine is given in combination with other CNS depressants.</li>
<li>Monitor BP in hypertensive patients since chlorpheniramine may elevate BP.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid driving a car and other potentially hazardous activities until drug response has been determined.</li>
<li>Avoid or minimize alcohol intake. Antihistamines have additive effects with alcohol.</li>
<li>Report any of the following: tinnitus or palpitations.</li>
<li>Consult physician before taking additional OTC drugs for allergy relief.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>